Key Performance
More- Earnings Score: 30
- Momentum Score: 7
- True Yield: N/A
- Financial Health Score: 59
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Prestige Consumer Healthcare (PBH) shares dropped over 11% on May 14, 2026, after the company reported significant revenue declines and production problems at its recently acquired Pillar5 facility. The facility, which was supposed to resolve Clear Eyes supply chain constraints, failed to deliver expected results. Q4 2026 revenues fell 5% year-over-year, with North America OTC Eye & Ear Care declining 20.6%. Hagens Berman has opened an investigation into whether the company adequately disclosed these issues to investors.
06/23/2026, 3:52 PM • GlobeNewswire
Pomerantz LLP is investigating potential securities fraud claims against Prestige Consumer Healthcare Inc. following the company's May 13, 2026 earnings announcement that revealed a 4.5% organic revenue decline and production issues with Clear Eyes products. The stock fell 11.35% to $45.93 per share on May 14, 2026, prompting the investigation into whether company officers and directors engaged in unlawful business practices.
06/09/2026, 1:59 PM • GlobeNewswire
The National Advertising Division reviewed advertising claims for eosera Inc.'s Ear Wax MD product in a challenge brought by Prestige Consumer Healthcare Inc. (marketer of Debrox). NAD found some establishment and mechanism-of-action claims were supported, but recommended discontinuing or modifying comparative superiority claims and unqualified effectiveness claims that overstated results. eosera agreed to comply with NAD's recommendations.
04/23/2026, 1:00 PM • GlobeNewswire
Prestige Bets $1 Billion On World's Most Iconic Nasal Strip
Prestige Consumer Healthcare announced a definitive agreement to acquire the Breathe Right brand for $1.045 billion. The acquisition will expand Prestige's consumer health portfolio in sleep and breathing categories and includes other brands like Dimetapp. The deal is expected to close in H1 fiscal 2027 and should boost margins and free cash flow. However, the stock shows technical weakness, trading below its moving averages with negative MACD signals.
03/20/2026, 7:56 AM • Benzinga
Prestige Consumer Healthcare has agreed to acquire Breathe Right® and other brands from Foundation Consumer Healthcare for $1.045 billion ($900 million net of tax benefits). The acquisition includes the iconic #1 nasal strip brand and other established brands like Dimetapp® and Anbesol®. The deal is expected to close in fiscal 2027 and is projected to be immediately accretive to margins and EPS, with strong free cash flow generation supporting rapid deleveraging.
03/20/2026, 6:15 AM • Benzinga
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.
02/13/2026, 11:26 AM • Benzinga
Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results
Prestige Consumer Healthcare will release its fiscal 2026 second quarter and first half earnings on November 6, 2025, before market opening, with a conference call at 8:30 a.m. ET to discuss results.
10/06/2025, 5:00 PM • GlobeNewswire
Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference
Prestige Consumer Healthcare will present at the Barclays Global Consumer Staples Conference, offering a live webcast of the event for investors and interested parties.
09/04/2025, 7:00 AM • GlobeNewswire
